Abstract
A 73-year-old woman with metastatic vaginal mucosal melanoma that had progressed on
ipilimumab and nivolumab experienced clinical and radiographic complete response to
dual checkpoint inhibitor immunotherapy given in combination with high-dose plus low-dose
radiation. General characteristics and treatment options in this disease are highlighted.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Gynecologic OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Combined-modality therapy for patients with regional nodal metastases from melanoma.Int. J. Radiat. Oncol. Biol. Phys. 2006; 64: 106-113
- Mucosal melanoma: new insights and therapeutic options for a unique and aggressive disease.Oncology (Williston Park). 2017; 31: e23-e32
- Cancer Staging Manual.8th ed. Springer International Publishing, Switzerland2017
- Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.CA Cancer J. Clin. 2017; 67: 472-492
- Final version of 2009 AJCC melanoma staging and classification.J. Clin. Oncol. 2009; 27: 6199-6206
- Malignant melanoma of the vulva and vagina: a US population-based study of 1863 patients.Am. J. Clin. Dermatol. 2020; 21: 285-295
- Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases.Ann. Surg. Oncol. 2015; 22: 1959-1966
- Management of primary melanoma of the female urogenital tract.Lancet Oncol. 2008; 9: 973-981
- Immunohistochemical expression of p16 in melanocytic lesions: an updated review and meta-analysis.Arch. Pathol. Lab. Med. 2018; 142: 815-828
- Immunohistochemical profiling of conjunctival melanocytic intraepithelial lesions, including Sox10, Hmb45, Ki67, and P16.Am J. Ophthalmol. 2021 Feb; 222 (Epub 2020 Sep 28. PMID: 33002486): 148-156https://doi.org/10.1016/j.ajo.2020.09.033
- Mucosal melanoma: a literature review.Curr. Oncol. Rep. 2018; 20: 28
- Efficacy and safety of nivolumab alone or in combination with Ipilimumab in patients with mucosal melanoma: a pooled analysis.J. Clin. Oncol. 2017; 35: 226-235
- Surveillance, Epidemiology and End Results.(Available from:)
- The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society.Cancer. 1998; 83: 1664-1678
- Incidence of noncutaneous melanomas in the U.S.Cancer. 2005; 103: 1000-1007
- Primary malignant melanoma of the vagina: a case report and review of the current treatment options.Eur. J. Obstet. Gynecol. Reprod. Biol. 2005; 121: 243-248
- Melanoma of the lower genital tract: prognostic factors and treatment modalities.Gynecol. Oncol. 2018; 150: 180-189
- Primary mucosal melanoma.J. Am. Acad. Dermatol. 2007; 56: 828-834
- Primary mucosal melanomas: a comprehensive review.Int. J. Clin. Exp. Pathol. 2012; 5: 739-753
- Genital and anorectal mucosal melanoma is associated with cutaneous melanoma in patients and in families.Br. J. Dermatol. 2013; 169: 594-599
- Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence.Cancer Imaging. 2013; 13: 626-632
- Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012.Eur. J. Cancer. 2012; 48: 2375-2390
- Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas.Int. J. Gynecol. Cancer. 2014; 24: S117-S122
- Phase II randomized trial comparing high-dose IFN-alpha2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.Clin. Cancer Res. 2013; 19: 4488-4498
- Vulvar and vaginal melanoma: case series and review of current management options including neoadjuvant chemotherapy.Gynecol. Oncol. 2013; 129: 533-537
- Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.Melanoma Res. 2004; 14: 517-520
- A literature overview of primary cervical malignant melanoma: an exceedingly rare cancer.Crit. Rev. Oncol. Hematol. 2012; 81: 185-195
- Management of melanomas of the female genital tract.Curr. Opin. Oncol. 2008; 20: 565-569
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation.N. Engl. J. Med. 2011; 364: 2507-2516
- Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.J. Clin. Oncol. 2013; 31: 3182-3190
- A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: a trial of the ECOG-ACRIN Cancer Research Group (E2607).Cancer. 2017; 123: 2688-2697
- High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.Expert Opin. Drug Saf. 2017; 16: 1347-1357
- Improved survival with ipilimumab in patients with metastatic melanoma.N. Engl. J. Med. 2010; 363: 711-723
- Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma.J. Clin. Oncol. 2015; 33: 1889-1894
- Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.Eur. J. Cancer. 2014; 50: 121-127
- Ipilimumab for patients with advanced mucosal melanoma.Oncologist. 2013; 18: 726-732
- Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma.Cancer Immunol. Immunother. 2019; 68: 1171-1178
- The efficacy of anti-PD-1 agents in acral and mucosal melanoma.Cancer. 2016; 122: 3354-3362
- Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.J. Clin. Oncol. 2014; 32: 1020-1030
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.Lancet. 2014; 384: 1109-1117
- Vaginal primary malignant melanoma: a rare and aggressive tumor.Case Rep. Obstet. Gynecol. 2013; 2013: 137908
- Primary malignant melanoma of the vagina.Obstet. Gynecol. 2010; 116: 1358-1365
- Clinical trial of carbon ion radiotherapy for gynecological melanoma.J. Radiat. Res. 2014; 55: 343-350
- Malignant melanoma of the vagina and locoregional control: radical surgery revisited.Gynecol. Oncol. 1998; 71: 476-480
- Treatment approach and outcomes of vaginal melanoma.Int. J. Gynecol. Cancer. 2013; 23: 1484-1489
- Whole body irradiation; radiobiology or medicine?.Br. J. Radiol. 1953; 26: 234-241
- Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system.Genome Med. 2019; 11: 40
- Use of multi-site radiation therapy for systemic disease control.Int. J. Radiat. Oncol. Biol. Phys. 2021 Feb 1; 109 (Epub 2020 Aug 13. PMID: 32798606): 352-364https://doi.org/10.1016/j.ijrobp.2020.08.025
- Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma.J. Immunother. Cancer. 2020; : 8(2)
- Radiation therapy for malignant melanoma.Surg. Clin. North Am. 2003; 83: 323-342
- The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study.Int. J. Radiat. Oncol. Biol. Phys. 1986; 12: 867-872
- Clinical radiobiology of malignant melanoma.Radiother. Oncol. 1989; 16: 169-182
- Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy.Cancer Res. 2017; 77: 839-850
- Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response.J. Transl. Med. 2014; 12: 262
- Systemic antitumor effects and abscopal responses in melanoma patients receiving radiation therapy.Oncology. 2020; 98: 202-215
- Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials.Lancet Respir. Med. 2020 Oct 20; (S2213-2600(20)30391-X; Epub ahead of print. Erratum in: Lancet Respir Med. 2021 Mar;9(3):e29. PMID: 33096027.)https://doi.org/10.1016/S2213-2600(20)30391-X
- Using immunotherapy to boost the abscopal effect.Nat. Rev. Cancer. 2018; 18: 313-322
- The role of radiation oncology in immuno-oncology.Oncologist. 2019; 24: S42-S52
- Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy.J. Immunother. Cancer. 2019; 7: 237
- Phase II trial of Ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses.Cancer Immunol Res. 2019; 7: 1903-1909
Article info
Publication history
Published online: March 29, 2021
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
